
Podcast #21 · 19 Aug 2025
Prostate Tumor Board: Risk Stratification & Treatment Strategies
- Radiation Oncology
- Prostate Cancer
- Medical Oncology
- Prostate-Specific Membrane Antigen PET (PSMA PET)
- Androgen Deprivation Therapy (ADT)
- Urologic Oncology
- Active Surveillance
- Radioligand Therapy
- Oligometastatic Disease
- Radiation Therapy
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.
This podcast is supported by
Timestamps
More about this episode
The multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.

